
               
               
               7 DRUG INTERACTIONS
               
                  Co-administration of oral ketoconazole 200Â mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX, retapamulin is unlikely to affect the metabolism of other P450 substrates.
                  The effect of concurrent application of ALTABAX and other topical products to the same area of skin has not been studied.
               
               
            
         